Capricor Therapeutics Inc. - CAPR EV/EBITDA Multiple

Corporate emblem and logo of Capricor (CAPR)

Capricor Therapeutics develops cellular therapies to combat rare genetic pathologies, leveraging collaborations with scientific centers and pharmaceutical behemoths. This EV/EBITDA chart, with a value of 0.00, reflects price action driven by reliance on Asian raw material imports and logistical risks. Meanwhile, a narrow focus on Duchenne muscular dystrophy therapy creates a high dependency of the share price on the outcome of final tests.

CAPR (Capricor Therapeutics Inc.) EV/EBITDA Multiple history from 11/23/2025 to 11/11/2026

CAPR (capricor.com): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Capricor Therapeutics, Inc.|CAPR - Broker Consensus Forecast
- issuer market value details:
Market Capitalization Capricor Therapeutics, Inc.|CAPR - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Capricor Therapeutics|CAPR - Book Capitalization|Market Value to Book Value Ratio capricor.com|CAPR - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Capricor Therapeutics|CAPR - Long-Term Liabilities to Capital|Short-Term Debt to Equity Capricor Therapeutics, Inc.|CAPR - Company Debts|Debt to Book Capitalization Ratio Capricor Therapeutics, Inc.|CAPR - Long-Term Debt|Company Short-Term Debts Capricor Therapeutics|Quick Liquidity Indicator capricor.com
- net income and valuation multiples indicators:
CAPR - Company Net Income|Projected Future Earnings Capricor Therapeutics|CAPR - Price to Earnings Ratio|Forward P/E Multiple Capricor Therapeutics, Inc.|CAPR - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Capricor Therapeutics, Inc.|CAPR - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months Capricor Therapeutics|CAPR - Earnings per share for the trailing year|Quarterly EPS earnings growth capricor.com|CAPR - Expected net earnings per share growth this year|Earnings growth forecast for next year Capricor Therapeutics
Summary company analytics:CAPR (Capricor)
Original product of Capricor Therapeutics, Inc.

The ratio is calculated as the total enterprise value (market capitalization plus net debt) divided by earnings before interest, taxes, depreciation, and amortization. This metric determines the payback period of assets, excluding the impact of the tax regime and debt load. For Capricor Therapeutics (CAPR), with its capital-intensive neurological research, this is a critical marker for the efficiency of managing billion-dollar investments. Analyzing the EV/EBITDA chart allows for the identification of points where the company's capacities are undervalued.

Competitor analysis

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jazz Pharma JAZZ|CYTK: Enterprise Value to Operating Income Before Depreciation|PTC Therapeutics, Inc. - EV/EBITDA Multiple|Company Value to EBITDA scholarrock.com|CNTA (Centessa) - Enterprise Value to EBITDA Ratio|Dyne Therapeutics Inc (DYN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Edgewise Pharma|RAPP: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alumis Inc. (ALMS)|ZVRA - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Contineum Therapeutics CTNM|Larimar Therapeutics Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TRDA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Channel Pharma|MNOV: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple serinatherapeutics.com SER|Enterprise Value to EBITDA Ratio BTAI|Company Value to EBITDA ProMIS PMN|EV/EBITDA Multiple APUS|Enterprise Value to EBITDA Ratio aeonbiopharma.com AEON|EV/EBITDA Multiple NLSP (NLS Pharmaceutics)|EV/EBITDA Multiple Bionomics Ltd. BNOX|HUGE - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio RETA